January 16, 2019 Smaller groups await Bristol-Myers Squelgene fallout Celgene had many fingers in many pies – so what will happen now to its smaller collaborators?
July 26, 2018 Storm hopes to rain on Accent’s parade Epigenetics has so far failed to live up to the hype. But one UK player, Storm Therapeutics, still hopes to make a mark in a new field, RNA therapeutics.